POLISENO, LAURA
 Distribuzione geografica
Continente #
AS - Asia 1.361
NA - Nord America 872
EU - Europa 444
SA - Sud America 192
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.907
Nazione #
US - Stati Uniti d'America 827
SG - Singapore 533
CN - Cina 291
HK - Hong Kong 160
VN - Vietnam 152
BR - Brasile 150
IT - Italia 119
NL - Olanda 96
FR - Francia 68
JP - Giappone 57
KR - Corea 48
GB - Regno Unito 33
BD - Bangladesh 27
DE - Germania 27
FI - Finlandia 27
IN - India 27
CA - Canada 25
AR - Argentina 16
PL - Polonia 16
TR - Turchia 10
ES - Italia 9
EC - Ecuador 8
ZA - Sudafrica 8
IL - Israele 7
IQ - Iraq 7
SA - Arabia Saudita 6
UZ - Uzbekistan 6
IE - Irlanda 5
MX - Messico 5
RU - Federazione Russa 5
SE - Svezia 5
CO - Colombia 4
ID - Indonesia 4
KE - Kenya 4
MA - Marocco 4
PH - Filippine 4
PK - Pakistan 4
PY - Paraguay 4
UA - Ucraina 4
BB - Barbados 3
BG - Bulgaria 3
EE - Estonia 3
EG - Egitto 3
KZ - Kazakistan 3
ML - Mali 3
TN - Tunisia 3
VE - Venezuela 3
AT - Austria 2
BE - Belgio 2
CL - Cile 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GR - Grecia 2
JM - Giamaica 2
JO - Giordania 2
KH - Cambogia 2
LT - Lituania 2
LV - Lettonia 2
PE - Perù 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BZ - Belize 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GN - Guinea 1
GP - Guadalupe 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LR - Liberia 1
MD - Moldavia 1
MZ - Mozambico 1
NA - Namibia 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SN - Senegal 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.907
Città #
Singapore 351
Santa Clara 184
Hong Kong 159
San Jose 155
Hefei 109
Ashburn 95
Beijing 68
Los Angeles 68
Ho Chi Minh City 61
Seoul 48
Tokyo 47
Lauterbourg 42
Hanoi 33
Amsterdam 15
Lappeenranta 14
Warsaw 14
Helsinki 13
São Paulo 13
Da Nang 12
Frankfurt am Main 12
New York 11
Dallas 10
Pisa 10
Montreal 9
Phoenix 9
Cascina 8
Council Bluffs 8
Düsseldorf 8
Portsmouth 8
Atlanta 7
Buffalo 7
Chennai 7
Guangzhou 7
Milan 7
Minamishinagawa 7
Orem 7
Paris 7
Brooklyn 6
Haiphong 6
Rome 6
Tashkent 6
Toronto 6
Denver 5
Dublin 5
Elk Grove Village 5
Houston 5
London 5
Stockholm 5
Bengaluru 4
Biên Hòa 4
Brasília 4
Charlotte 4
Guayaquil 4
Jeddah 4
Newark 4
Rio de Janeiro 4
Ankara 3
Bamako 3
Bogotá 3
Bridgetown 3
Buenos Aires 3
City of London 3
Contagem 3
Florence 3
Jundiaí 3
Kyiv 3
Lissone 3
Manchester 3
Mexico City 3
Mumbai 3
Nairobi 3
Naples 3
Nha Trang 3
Providence 3
Quito 3
San Giuseppe Vesuviano 3
Santa Maria 3
Vicenza 3
Yerres 3
Acalanes Ridge 2
Amman 2
Aracaju 2
Asunción 2
Baghdad 2
Bangkok 2
Belo Horizonte 2
Betim 2
Bismarck 2
Bologna 2
Boston 2
Brussels 2
Cairo 2
Can Tho 2
Cape Town 2
Cavallino 2
Chicago 2
Chongqing 2
Concórdia 2
Falkenstein 2
Guarulhos 2
Totale 1.853
Nome #
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 93
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells 90
PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation 90
A eutherian-specific microRNA controls the translation of Satb2 in a model of cortical differentiation 85
A Network of MicroRNAs and mRNAs Involved in Melanosome Maturation and Trafficking Defines the Lower Response of Pigmentable Melanoma Cells to Targeted Therapy 83
Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA 78
High-Throughput Identification of miRNA-Target Interactions in Melanoma Using miR-CATCHv2.0 74
Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma 73
GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma 68
Modified Cas9-Guided Oxford Nanopore Technology Sequencing Uncovers Single and Multiple Transgene Insertion Sites in a Zebrafish Melanoma Model 63
Enhancing the Anticancer Activity of Attenuated Listeria monocytogenes by Cell Wall Functionalization with "Clickable" Doxorubicin 63
MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response 62
Coding, or non-coding, that is the question 60
Context-dependent miR-204 and miR-211 differentially affect the biological properties of amelanotic and melanotic melanoma cells 60
Inducible modulation of miR-204 levels in a zebrafish melanoma model 59
Editorial: Role of pigmentation in melanoma 58
A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells 57
CRISPR/Cas Technologies Applied to Pseudogenes 57
Inibizione dell'espressione di BCL2 in cellule MCF7 mediante short interfering RNA 56
Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System 56
Development of a yeast-based system to identify new hBRAFV600E functional interactors 54
PTENP1 is a ceRNA for PTEN: it's CRISPR clear 52
Identification of BRAF 3'UTR Isoforms in Melanoma 52
Biosafety and Biokinetics of Noble Metals: The Impact of Their Chemical Nature 52
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22 52
Biological role of miR-204 and miR-211 in melanoma 51
In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System 50
Modulazione tra fenotipo sintetico e contrattile: un modello in vitro per studiare l'attivazione di cellule muscolari lisce di coronarie 48
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 48
Alkaline Phosphatase-Positive Immortal Mouse Embryo Fibroblasts Are Cells in a Transitional Reprogramming State Induced to Face Environmental Stresses 48
Efficacy of amphipathic oligopeptide to shuttle and release a cis-acting DNA decoy into human cells 48
The Proto-Oncogene LRF Is under Post-Transcriptional Control of miR-20a: Implications for Senescence 48
Proteomics pipeline for phosphoenrichment and its application on a human melanoma cell model 46
The sensitivity of MCF10A breast epithelial cells to alkylating drugs is enhanced by the inhibition of O-6 methylguanine-DNA methyltransferase transcription with a synthetic double strand DNA oligonucleotide 46
Methods for the Identification of PTEN-Targeting MicroRNAs 46
Pseudogenes-functions and protocols 45
Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma 45
The landscape of BRAF transcript and protein variants in human cancer 43
Pseudogenes-functions and protocols, second edition 41
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma 41
The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage 39
The non-coding rna journal club: Highlights on recent papers—9 36
The Non-Coding RNA Journal Club: Highlights on Recent Papers—14 35
The sensitivity of MCF10A breast epithelial cells to alkylating drugs is enhanced by the inhibition of O6-methylguanine-DNA methyltransferase transcription with a synthetic double strand DNA oligonucleotide 35
The activity of short interfering RNAs can be inferred from the energy profile 32
Role of the oncogenic BRAFV600E in the osmostress response of yeast Saccharomyces cerevisiae 32
Long non-coding RNAs in cancer: implications for personalized therapy 31
The Proto-Oncogene LRF is under Post-Transcriptional Control of MiR-20a:Implications of senescence 30
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 29
MicroRNAs modulate the angiogenic properties of HUVECs 29
Resting smooth muscle cells as a model for studying vascular cell activation 27
Bidirectional switch between synthetic and contractile phenotypes: an in vitro model to study the activating of coronary smooth muscle cells 27
The Mycomembrane Differentially and Heterogeneously Restricts Antibiotic Permeation 26
microrna 20 regulates the level of the proto-oncogene LRF and activate cellular senescence in mouse embryo fibroblasts 25
Application of ribozyme strategy to study the sensitivity of breast cancer cells to cytotoxic drugs 25
PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research 24
Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes 22
Protein expression profiling and phenotype modulation 22
The analysis of dose response curve comes in useful for the assembly of multi-siRNAs expressing cassettes 15
Identification of active siRNAs against IGF-IR of porcine coronary smooth muscle cells in a heterologous cell line 15
PTEN ceRNA networks in human cancer 14
RNA-based drugs: From RNA interference to short interfering RNAs 13
miRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation 13
Pseudogenes: Newly discovered players in human cancer 13
Pseudogenes in human cancer 12
The energy profiling of short interfering RNAs is highly predictive of their activity 12
Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment 11
Bcl2-negative MCF7 cells overexpress p53: Implications for the cell cycle and sensitivity to cytotoxic drugs 10
Landscape of BRAF transcript variants in human cancer 10
null 8
null 7
null 7
Unveiling a Novel Molecular Interaction and Pro-Metastatic Signaling Cascades Driven by KRIT1 7
null 6
null 5
null 5
null 5
null 5
null 5
null 4
null 4
null 4
null 4
null 4
null 3
null 3
null 3
Totale 3.094
Categoria #
all - tutte 10.204
article - articoli 8.514
book - libri 332
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 701
Totale 19.751


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202415 0 0 0 0 0 0 0 0 1 0 12 2
2024/20251.219 8 2 69 43 322 56 18 57 53 124 257 210
2025/20261.825 94 130 130 272 299 126 291 69 100 179 74 61
2026/202735 35 0 0 0 0 0 0 0 0 0 0 0
Totale 3.094